Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100316 · ClinicalTrials.gov registry record · Phase 2
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05100316 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT05100316, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers. No treatment intervention will occur as part of this screening study.
Interventions
- OTHER Screening Platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2022-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05100316
The ClinicalTrials.gov registry entry for NCT05100316 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Screening Platform is the first listed.
NCT05100316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05100316 about?
NCT05100316 is a clinical study titled "Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials". This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers. No treatment intervention will occur as part of this screening study.
What is the current status of trial NCT05100316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-12-16. Estimated completion is 2022-10-04.
What interventions are being tested in trial NCT05100316?
The interventions under investigation include: Screening Platform (OTHER).
Who is sponsoring clinical trial NCT05100316?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.